Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of a user-friendly next generation epigenomic chip adaptable to automation workflows

Award Number: R43HG013631
ORGANIZATION: NATIONAL HUMAN GENOME RESEARCH INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2024
PERIOD OF PERFORMANCE END DATE: 12/31/2024

Group Awards By:

View Award Description

Development of a user-friendly next generation epigenomic chip adaptable to automation workflows - In this Phase I SBIR study, AtlasXomics will develop a next-generation spatial deposition process to expand tissue type compatibility, minimize end-user processing, and allow adaptation into larger automation workflows. Epigenetics is critical in regulating gene expression in healthy and diseased tissue cells. Incorporating genome-wide epigenetics illuminates research into cancer, neurodegenerative diseases, and systems biology. Systematic epigenomic tissue analysis will allow researchers to bring to bear the power of spatial multi-modal omics to a broad range of disease research. An epigenomics tool accessible to bench scientists remains an unmet need. AtlasXomics launched the first genome-wide spatial epigenomics tool, spatial-ATAC-seq, built on our Deterministic Barcoding in Tissue for spatial omics sequencing (DBiT-seq) platform. An automatable version of our DBiT-seq device will provide this missing puzzle piece but requires greater flexibility, throughput, and ease of use. Early adopters applied our assays to human melanoma, brain cancer, and neurodegenerative diseases. Based on positive early adopter feedback, we have set key objectives for a next-generation product with 1) improved ease of use, 2) greater flexibility for application to a wider array of tissue types, 3) larger field of view (FOV) approaching single-cell resolution, and 4) at a lower cost for large-scale epigenomics studies. To meet this critical need, AtlasXomics will develop a process substantially reducing the end user’s process steps and pain points, delivering a widely accessible spatial platform. We have developed a prototype FlowGel process using the current commercial consumable (25um resolution, 2.5x2.5mm FOV) to map chromatin accessibility in fresh-frozen mouse brains. Once finalized, the process and consumables will be transferable to all other AtlasXomics applications currently in development. The positive results from this proof-of-principal study set the groundwork for AtlasXomics to deliver a more robust, user-friendly, low-cost spatial epigenomic product. Aim 1: Prove the FlowGel at a larger FOV dramatically minimizes researchers’ bench time, reducing human error and improving quality. Aim 2: Make the FlowGel chip and hardware and demonstrate their superior performance with various tissue types over our current commercial technology. Transition to Phase II. We will supply three customers with FlowGel kits and training to carry out FlowGel-enabled spatial assays and map out product requirements for small labs and more extensive automated operations.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	ATLASXOMICS INC	290 CONGRESS AVE	NEW HAVEN	CT	06519	SOUTH CENTRAL CT	USA	Human Genome Research	000	1	5/2/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $399,929 )
2024	2024	ATLASXOMICS INC	290 CONGRESS AVE	NEW HAVEN	CT	06519	SOUTH CENTRAL CT	USA	Human Genome Research	000	1	6/20/2024	NEW	$399,929
														Subtotal = $399,929

Grand Total All Awards = $399,929

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a user-friendly next generation epigenomic chip adaptable to automation workflows

Award Number: R43HG013631

ORGANIZATION: NATIONAL HUMAN GENOME RESEARCH INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2024

PERIOD OF PERFORMANCE END DATE: 12/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer